Tuesday, July 10, 2018

Crinetics Sets Estimated IPO Range

San Diego-based Crinetics Pharmaceuticals, a pharmaceuticals firm focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, has set its estimated IPO range, saying in a filing that it is looking to sell 5,000,000 shares of its stock at between $15.00 and $17.00 per share.

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.